Pseudoprogression as an adverse event of glioblastoma therapy

We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or neither (nP). We examined potential associations with clinical, molecular, and...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Med
Главные авторы: Balaña, Carmen, Capellades, Jaume, Pineda, Estela, Estival, Anna, Puig, Josep, Domenech, Sira, Verger, Eugenia, Pujol, Teresa, Martinez‐García, Maria, Oleaga, Laura, Velarde, JoseMaria, Mesia, Carlos, Fuentes, Rafael, Marruecos, Jordi, Del Barco, Sonia, Villà, Salvador, Carrato, Cristina, Gallego, Oscar, Gil‐Gil, Miguel, Craven‐Bartle, Jordi, Alameda, Francesc
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2017
Предметы:
Clinical Cancer Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5727237/
https://ncbi.nlm.nih.gov/pubmed/29105360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1242
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы